Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

FATE $7.24 2.2800 +45.97%
NYMX $1.47 0.1400 +10.53%
PGNX $5.53 0.5100 +10.16%
VRML $1.90 0.1600 +9.20%
ARRY $7.10 0.5300 +8.07%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

TLOG $2.40 -1.3800 -36.51%
ARQL $1.81 -0.2000 -9.95%
TCON $10.35 -0.7899 -7.09%
CVM $0.97 -0.0600 -5.83%
VBLT $3.72 -0.2200 -5.58%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | Next > | Last >>

Angry Over Drug Prices, More States Push Bills for Pharma to Disclose Costs

(Wall Street Journal/Pharmalot blog) Apr 24, 2015 - Should drug makers be required to disclose their costs to justify rising prices?
read article (paid subscription required) 

Breast Cancer Gene Test Becoming More Afforrdable, Accessible

(KSAT 12 ABC [San Antonio, TX]) Apr 23, 2015 - Doctors at the Cancer Therapy and Research Center at the University of Texas Health Science Center are awaiting the reaction to news that several companies will be dropping the price of breast cancer gene testing dramatically, making the BRCA 1 and 2 test accessible to many who could not afford it.
read article 

Targazyme, Inc., Announces FDA Concurrence on Targazyme's Special Protocol Assessment for a Planned Phase 3 Registration Trial for the Treatment of Patients With Hematologic Malignancies

(Yahoo! Finance) Apr 23, 2015 - Targazyme, Inc., announced today that the U.S. Food and Drug Administration (FDA) and Targazyme have reached concurrence on the company's Special Protocol Assessment (SPA) application for its Phase 3 registration trial.
read article 

Thyroid Group Issues Guidelines for Kids' Nodule Management

(MedPage Today) Apr 23, 2015 - Range of options preferred over 'one-size-fits-all' treatments.
read article (free registration required) 

ONO Submits Additional Indication Application for OPDIVO® (Nivolumab) for the Treatment of Patients with Unresectable, Advanced or Recurrent Non-Small Cell Lung Cancer (Except Non-Squamous Cell Carcinoma)

(ONO) Apr 22, 2015 - ONO PHARMACEUTICAL CO., LTD. announced today that it has submitted an additional indication application for the human anti-human programmed cell death-1 (PD-1) monoclonal antibody “OPDIVO® 20mg, 100mg Inj.”
read corporate press release 

Bayer Submits Marketing Authorization for Radium-223 Dichloride to Treat Prostate Cancer with Bone Metastases in Japan

(Bayer) Apr 24, 2015 - Bayer HealthCare has submitted an application for marketing authorization to the Ministry of Health, Labour and Welfare (MHLW) in Japan for radium-223 dichloride (radium-223) solution for injection for the treatment of prostate cancer patients with bone metastases.
read corporate press release 

Animal Testing and Its Gifts To Humans

(Wall Street Journal) Apr 23, 2015 - Patients with aggressive brain tumors finally have reason for hope. Thanks to the work of scientists and physicians at Duke University, an experimental new treatment for glioblastoma multiforme, or GBM—an aggressive tumor that kills about 12,000 people in the U.S. each year—is saving the lives of patients who, just months ago, had little hope of survival.
read article (paid subscription required) 

Refusal of the Marketing Authorisation For Lympreva (dasiprotimut-T)

(EMA) Apr 23, 2015 - On 23 April 2015, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Lympreva, intended for the treatment of patients with follicular non-Hodgkin’s lymphoma.
read article 

Insurance Coverage for Mammograms Jeopardized By New Guidelines, Congresswoman and Breast Cancer Survivor Says

(Washington Post) Apr 23, 2015 - Earlier this week, the U.S. Preventive Services Task Force, an independent group of doctors and health-care experts, issued draft recommendations on mammography for women at various ages.
read article (free registration required) 

Oncologist Highlights Primary Reasons for the High Cost of Cancer Care

(AJMC) Apr 23, 2015 - With the rising prices of innovative oncology treatments, many of which fall under specialty pharmaceuticals, curbing the cost of care is high on the agenda of healthcare providers.
read article 

Payers and Providers Discuss Pros and Cons of Oncology Payment Reform

(AJMC) Apr 23, 2015 - A general session at the Community Oncology Conference, Community Oncology 2.0, Moving Forward on Payment Reform, was a panel discussion that saw participation by 2 providers and a payer.
read article 

Can a Compound in Red Wine Help Fight Cancer? How Supplements Can Be Promising Disease-Fighters

(Huffington Post) Apr 23, 2015 - In the war against cancer, we've taken many steps forward, thanks to science and treatments like radiation and chemotherapy.
read article 

Combo Approach Fails in Liver Cancer Trial

(MedPage Today) Apr 23, 2015 - Combining an angiogenesis inhibitor and transcatheter arterial chemoembolization doesn't work.
read article (free registration required) 

New Data Shows Irreversible Electroporation Nearly Doubles Overall Survival of Patients with Locally Advanced Pancreatic Cancer When Added to Standard Therapy

(Sacramento Business Journal) Apr 24, 2015 - University of Louisville announced today results from the Soft Tissue Ablation Registry (STAR), demonstrating that irreversible electroporation (IRE) with the NanoKnife®System, in combination with chemotherapy, doubled the overall survival rate of locally advanced (Stage III) pancreatic cancer patients to nearly 24 months.
read article 

Standard Clinical Assays Can Obscure The Diversity Of Breast Cancer Subtypes

(Clinical Leader) Apr 24, 2015 - Classification systems that categorize breast cancers based on estrogen receptor (ER), progesterone receptor (PR), and HER2 expression levels may obscure the heterogeneity of other key tumor features, according to a new study published in The Oncologist on April 23, 2015.
read article 

An End to Cancer Pain? Dentistry Researcher Finds the Pain Trigger

(University of Toronto - Faculty of Dentistry) Apr 23, 2015 - A new study led by Dr. David Lam has discovered the trigger behind the most severe forms of cancer pain. Released in top journal Pain this month, the study points to TMPRSS2 as the culprit: a gene that is also responsible for some of the most aggressive forms of androgen-fuelled cancers.
read article 

'Humanized' Mice Will Lead to Better Testing of Cancer Immunotherapies

(UCCC/In the Lab blog) Apr 23, 2015 - Human tumours grown in mouse models have long been used to test promising anti-cancer therapies. However, when a human tumour is transplanted into a mouse, the mouse immune system must be knocked down so that it doesn't attack the foreign tumour tissue, thus allowing the tumour to grow.
read article 

Walking Improves Mood, Boosts Energy in Cancer Survivors

(Medscape Medical News) Apr 23, 2015 - Two studies, one from Europe and one from the United States, advise cancer survivors to be physically active to reduce adverse effects from chemotherapy and improve their health-related quality of life (HRQOL).
read article (free registration required) 

Self-Reported Health Predicts Survival in Breast Cancer

(Medical Xpress/HealthDay News) Apr 24, 2015 - For older women with breast cancer, low self-rated health (SRH) and limited walking ability predict worse all-cause survival at five and 10 years, according to a study published in the April issue of the Journal of the American Geriatrics Society.
read article  

Brain Tumor Growth Stimulated by Nerve Activity in the Cortex, Study Finds

(Stanford Medicine) Apr 23, 2015 - New research shows that high-grade gliomas, the deadliest human brain tumors, increase their growth by hijacking some of the machinery of neuroplasticity, which normally helps the brain form new synapses.
read article 

How to Identify Drugs That Work Best For Each Patient

(MIT News) Apr 22, 2015 - Implantable device could allow doctors to test cancer drugs in patients before prescribing chemotherapy.
read article 

SEER Cancer Statistics Review (CSR) 1975-2012

(NCI) Apr 23, 2015 - The SEER Cancer Statistics Review (CSR), a report of the most recent cancer incidence, mortality, survival, prevalence, and lifetime risk statistics, is published annually by the Data Analysis and Interpretation Branch of the NCI.
read press release 

AZ Seals Immuno-Oncology Deals as Q1 Sales, Earnings, Slip

(PharmaTimes [UK]) Apr 24, 2015 - AstraZeneca has further singled out immuno-oncology as a central vein of its future business with three separate deals seeking to develop new therapies in the field.
read article 

POMALYST (pomalidomide) Label Update Including Progression-Free and Overall Survival Benefits Approved by U.S. FDA

(TheStreet) Apr 23, 2015 - Celgene Corporation today announced it has fulfilled the accelerated approval requirements for POMALYST ® (pomalidomide) based on results from MM-003, an international phase III study of POMALYST plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma patients.
read article 

Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Opdivo (nivolumab) for the Treatment of Advanced Melanoma in Both First-Line and Previously Treated Patients

(Bristol-Myers) Apr 24, 2015 - Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor, be granted approval for use in both first-line and previously treated patients with advanced (unresectable or metastatic) melanoma.
read corporate press release